MacroGenics reports Phase Ib/II data of margetuximab plus Keytruda to treat gastric and gastroesophageal junction cancer

MacroGenics Inc. (NASDAQ:MGNX) reported data from 51 evaluable patients with relapsed or refractory advanced HER2-positive gastric and gastroesophageal junction cancer with disease

Read the full 229 word article

User Sign In